Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 and Arginase1 Peptide Vaccine in MPN
NCT04051307Phase 2Completed
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Modified Peptides, Native Peptides, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1Long, ArgLong2 in polycythemia vera (PV), essential thrombocythemia (ET). Started Jul 2019; status: completed.
02
Drugs
PD-L1LongArgLong2
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04051307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051307.